

Patterns of Venous Thromboembolism Prophylaxis

Supplemental Anonymous 19-Question Web-Based Survey
Figure 1

Acute Leukemia VTE Prophylaxis

*1. In which country do you practice medicine?

- United States
 Other (please specify)

*2. If you are in the United States, in which state do you practice medicine?

State:

*3. What is your gender?

- Male
 Female
 Prefer not to answer

*4. What is your age?

- Under 20 years old
 20-30 years old
 30-40 years old
 40-50 years old
 50-60 years old
 60-70 years old
 70-80 years old
 Above 80 years old

*5. In what type of institution do you work?

- University-affiliated / public
 Private
 Veteran's Administration
 Military
 HMO
 Other (please specify)

Supplemental continued
Figure 1

6. What is the name of the institution in which you treat the acute leukemia patients?

*7. In what specialty do you have board certification? Please choose all that apply.

- Hematology
 Medical Oncology
 Not applicable
 Other (please specify)

*8. How many years post-fellowship training are you?

- 0-5 years
 6-10 years
 11-20 years
 21 or more years
 Not applicable

*9. Which of the following is closest to your primary job description?

- Clinician
 Clinical Researcher
 Clinical Educator
 Basic Science Researcher
 Other (please specify)

*10. What is your hospital's current approach to documentation?

- Paper medical records only
 Electronic medical records only (EMR)
 Mixture of both (i.e., in transition to EMR)

Patterns of Venous Thromboembolism Prophylaxis

Supplemental
Figure 1 continued*** 11. What is your hospital's current approach to provider orders?**

- Paper order entry only
- Electronic order entry (EOE)
- Mixture of both (i.e., in transition to EOE)

*** 12. About how many patients with acute leukemia are treated at your institution annually?**

- Less than 25
- 25-50
- 51-100
- 101-150
- ≥ 151
- Not sure

*** 13. About how many patients with acute leukemia do you treat each year?**

- Less than 25
- 25-50
- 51-100
- 101-150
- ≥ 151
- Not applicable

*** 14. Does your hospital have a VTE prophylaxis order set (either paper or electronic) specifically designed for:**

	Yes	No	Not sure
Acute leukemia patients?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Patients with hematologic malignancies?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Medical oncology patients?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

15. What do you most commonly use for VTE prophylaxis in acute leukemia patients (excluding acute promyelocytic leukemia and patients with disseminated intravascular coagulation) during induction therapy? Please choose all that apply.

- I do not use any VTE prophylaxis
- Ambulation alone
- TED stockings (graduated compression stockings)
- Intermittent pneumatic compression devices (i.e., IPC or SCDs)
- TEDS/SCDs
- Subcutaneous (SC) unfractionated heparin
- SC heparin + TEDS and/or SCDs
- SC low molecular weight heparin (LMWH)
- SC LMWH + TEDS and/or SCDs
- Fondaparinux
- Fondaparinux + TEDS and/or SCDs

If SC LMWH what is your preferred product?

Supplemental continued
Figure 1

16. What do you most commonly use for VTE prophylaxis in acute leukemia patients during consolidation therapy? Please choose all that apply.

- I do not use any VTE prophylaxis
- Ambulation alone
- TED stockings (graduated compression stockings)
- Intermittent pneumatic compression devices (i.e., IPC or SCDs)
- TEDS/SCDs
- Subcutaneous (SC) unfractionated heparin
- SC heparin + TEDS and/or SCDs
- SC low molecular weight heparin (LMWH)
- SC LMWH + TEDS and/or SCDs
- Fondaparinux
- Fondaparinux + TEDS and/or SCDs

If SC LMWH what is your preferred product?

17. If you use an anticoagulant for VTE prophylaxis at what platelet count threshold do you withhold it?

- 100,000/ul
- 75,000/ul
- 50,000/ul
- 30,000/ul
- Not applicable
- Other platelet count (xx/ul)

18. If you do NOT currently use VTE prophylaxis, what is the most important reason?

- Risk of VTE is low
- Risk of bleeding is high
- Absence of data supporting efficacy of VTE prophylaxis in these populations
- Not applicable
- Other (please specify)

19. What is your approach for VTE prophylaxis during induction therapy for patients with acute promyelocytic leukemia (APL)?

- I do not use any form of pharmacologic VTE prophylaxis in any patient with APL
- I do not use pharmacologic VTE prophylaxis if there is evidence of clinical bleeding
- I do not use pharmacologic VTE prophylaxis if there is evidence of disseminated intravascular coagulation (DIC) or thrombocytopenia
- I use pharmacologic VTE prophylaxis for all patients with APL
- Not applicable
- Other (please specify)

Done